Compare Stocks → One trade. One ticker. One week. (From Wealthpin Pro) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NASDAQ:ASLNNASDAQ:GANXNASDAQ:JAGXNASDAQ:LABPNASDAQ:NBSE Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeASLNASLAN Pharmaceuticals$0.47$0.61$0.39▼$4.69$7.68M1.45989,708 shs23,383 shsGANXGain Therapeutics$3.02-5.3%$4.04$2.00▼$5.65$48.98M0.43152,524 shs23,141 shsJAGXJaguar Health$0.16-4.8%$0.09$0.05▼$1.22$44.67M1.3550.48 million shs4.87 million shsLABPLandos Biopharma$22.50+1.4%$13.40$2.50▼$22.84$70.20M0.1421,812 shs2,820 shsNBSENeuBase Therapeutics$0.43+3.1%$0.69$0.39▼$4.80$1.63M0.83202,269 shs6,644 shs7 AI Stocks to Invest In: An Introduction to AI Investing For Self-Directed InvestorsAs the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceASLNASLAN Pharmaceuticals+0.21%-4.28%-28.06%-18.26%-88.76%GANXGain Therapeutics-5.90%+0.31%-12.60%-10.01%-35.43%JAGXJaguar Health+1.13%+3.03%+135.32%+47.74%-64.38%LABPLandos Biopharma+0.95%+3.18%+4.44%+367.78%+671.03%NBSENeuBase Therapeutics0.00%+0.26%-57.44%-32.12%-83.97%The system that called 2023’s top 7 stocks is at it again… (Ad)Look 2023 kind of sucked from a trading standpoint… Despite the market finishing 24% higher…. Just seven stocks did all of the work… Unless you were holding or actively trading those 7 stocks, your trading year probably wasn’t as fruitful as you had hoped… According to my research, my new trading system would have spotted all seven of the “Magnificent stocks” MONTHS before they reached the highs they are trading at today.Just follow this link here!MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationASLNASLAN Pharmaceuticals2.8965 of 5 stars3.55.00.00.03.00.80.6GANXGain Therapeutics3.5483 of 5 stars3.55.00.00.03.82.50.6JAGXJaguar HealthN/AN/AN/AN/AN/AN/AN/AN/ALABPLandos Biopharma0.2757 of 5 stars1.03.00.00.02.50.80.6NBSENeuBase TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/AAnalyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceASLNASLAN Pharmaceuticals3.00Buy$11.332,311.35% UpsideGANXGain Therapeutics3.00Buy$8.50181.46% UpsideJAGXJaguar HealthN/AN/AN/AN/ALABPLandos Biopharma2.00Hold$20.42-9.24% DownsideNBSENeuBase TherapeuticsN/AN/AN/AN/ACurrent Analyst RatingsLatest LABP, GANX, ASLN, JAGX, and NBSE Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/25/2024GANXGain TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$9.004/23/2024ASLNASLAN PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$9.004/23/2024GANXGain TherapeuticsOppenheimerSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform$9.004/15/2024ASLNASLAN PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$9.004/1/2024GANXGain TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$9.004/1/2024LABPLandos BiopharmaHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Neutral$50.00 ➝ $20.423/27/2024GANXGain TherapeuticsChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$6.003/18/2024ASLNASLAN PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$17.00 ➝ $9.003/13/2024ASLNASLAN PharmaceuticalsPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Overweight$15.00 ➝ $10.00(Data available from 4/25/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookASLNASLAN Pharmaceuticals$12M0.64N/AN/A($0.81) per share-0.58GANXGain Therapeutics$50K979.69N/AN/A$0.97 per share3.11JAGXJaguar Health$9.76M4.58N/AN/A$0.07 per share2.31LABPLandos Biopharma$18M3.90N/AN/A$10.20 per share2.21NBSENeuBase TherapeuticsN/AN/AN/AN/A$11.04 per shareN/AProfitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateASLNASLAN Pharmaceuticals-$44.22M-$2.74N/AN/AN/AN/A-8,454.87%-95.72%4/26/2024 (Estimated)GANXGain Therapeutics-$22.27M-$1.71N/AN/AN/AN/A-193.03%-123.21%5/10/2024 (Estimated)JAGXJaguar Health-$41.30MN/A0.00∞N/A-423.11%-837.11%-80.76%5/20/2024 (Estimated)LABPLandos Biopharma-$21.93M-$3.46N/AN/AN/AN/A-54.92%-49.09%5/10/2024 (Estimated)NBSENeuBase Therapeutics-$4.37M-$7.70N/A∞N/AN/A-99.74%-60.13%5/9/2024 (Estimated)Latest LABP, GANX, ASLN, JAGX, and NBSE EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails4/26/2024N/AASLNASLAN PharmaceuticalsN/A-$0.61-$0.61N/AN/AN/A4/12/2024Q4 2023ASLNASLAN PharmaceuticalsN/A-$0.78-$0.78-$0.78N/AN/A3/26/2024Q4 2023GANXGain Therapeutics-$0.32-$0.29+$0.03-$0.29N/AN/A3/21/2024Q4 2023LABPLandos Biopharma-$0.91-$0.99-$0.08-$0.99N/AN/ADividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthASLNASLAN PharmaceuticalsN/AN/AN/AN/AN/AGANXGain TherapeuticsN/AN/AN/AN/AN/AJAGXJaguar HealthN/AN/AN/AN/AN/ALABPLandos BiopharmaN/AN/AN/AN/AN/ANBSENeuBase TherapeuticsN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioASLNASLAN PharmaceuticalsN/A1.841.84GANXGain Therapeutics0.043.593.59JAGXJaguar Health6.332.001.34LABPLandos BiopharmaN/A6.096.09NBSENeuBase TherapeuticsN/A2.872.87OwnershipInstitutional OwnershipCompanyInstitutional OwnershipASLNASLAN Pharmaceuticals58.82%GANXGain Therapeutics11.97%JAGXJaguar Health12.04%LABPLandos Biopharma49.06%NBSENeuBase Therapeutics12.37%Insider OwnershipCompanyInsider OwnershipASLNASLAN Pharmaceuticals4.69%GANXGain Therapeutics11.00%JAGXJaguar Health0.16%LABPLandos Biopharma1.30%NBSENeuBase Therapeutics13.90%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableASLNASLAN Pharmaceuticals3516.35 million15.58 millionOptionableGANXGain Therapeutics2816.22 million14.44 millionOptionableJAGXJaguar Health49276.22 million275.77 millionNo DataLABPLandos Biopharma193.12 million3.08 millionNot OptionableNBSENeuBase Therapeutics373.75 million3.23 millionNot OptionableLABP, GANX, ASLN, JAGX, and NBSE HeadlinesSourceHeadlineNeuBase Therapeutics, Inc.: NeuBase Therapeutics Announces Receipt of Notice from Nasdaqfinanznachrichten.de - April 6 at 8:58 AMNeuBase Therapeutics Announces Receipt of Notice from Nasdaqglobenewswire.com - April 5 at 4:05 PMOnce-promising Pittsburgh biotech firm shutting down for goodtechnical.ly - March 27 at 8:33 PMWhy Neubase Therapeutics (NBSE) Shares Are Nosedivingmsn.com - March 27 at 10:32 AMNeuBase Therapeutics, ABVC BioPharma, Stoke Therapeutics among healthcare moversmsn.com - March 26 at 10:47 AMWhy Is NeuBase Therapeutics (NBSE) Stock Down 58% Today?investorplace.com - March 26 at 9:08 AMNeuBase Therapeutics sets shareholder meeting on dissolution planbizjournals.com - March 25 at 7:44 PMNeuBase Therapeutics Incedition.cnn.com - February 26 at 9:46 AMNeuBase Therapeutics, Inc. (NBSE)finance.yahoo.com - February 20 at 1:40 PMNeuBase Therapeutics Inc (O7P.BE)ca.finance.yahoo.com - January 20 at 12:17 AMMonitoring NeuBase Therapeutics Inc (NBSE) after recent insider movementsknoxdaily.com - January 1 at 2:48 PMCMU halts licensing agreement with NeuBase Therapeuticsbizjournals.com - December 22 at 7:16 PMPsychemedics Corporation Appoints Daniella Mehalik as VP - Financefinance.yahoo.com - November 27 at 10:19 AMNeuBase Therapeutics Inc NBSEmorningstar.com - November 6 at 11:41 PMNeuBase Therapeutics: Other Eventscbonds.com - October 21 at 8:32 AMNeuBase Therapeutics, Inc. (NBSE.MX)finance.yahoo.com - October 6 at 8:56 AMNeuBase Therapeutics Inc. (NBSE) gets rating Reiterated from H.C. Wainwrightknoxdaily.com - September 20 at 6:31 PMMassive Insider Trade At NeuBase Therapeuticsbenzinga.com - September 12 at 3:51 PMNeuBase falls after largest shareholder disposes of part stakemsn.com - September 12 at 3:51 PMNeuBase Therapeutics Issues Statement Regarding Filing By Shareholderfinance.yahoo.com - September 8 at 11:10 AMWhy Is NeuBase Therapeutics (NBSE) Stock Up 19% Today?markets.businessinsider.com - September 6 at 9:07 AMNBSE’s short interest falls to 41130.0 sharesknoxdaily.com - August 25 at 4:34 PMAnalysts Conflicted on These Healthcare Names: NeuBase Therapeutics (NBSE) and Centessa Pharmaceuticals (CNTA)markets.businessinsider.com - August 16 at 7:45 AMNeuBase Therapeutics (NASDAQ: NBSE)fool.com - August 6 at 6:46 PMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCompany DescriptionsASLAN PharmaceuticalsNASDAQ:ASLNASLAN Pharmaceuticals Limited, a clinical-stage immunology focused biopharmaceutical company, engages in developing various treatments to transform the lives of patients. The company's clinical portfolio comprises ASLAN004, a monoclonal antibody that targets the IL-13 receptor a1 subunit which is being developed for the treatment of atopic dermatitis and other immunology indications; and ASLAN003, a small-molecule inhibitor of dihydroorotate dehydrogenase for the treatment of autoimmune diseases. It has a joint venture with JAGUAHR Therapeutics Pte. Ltd. and Bukwang Pharmaceutical Co., Ltd. to develop immuno-oncology therapeutics for markets targeting the AhR pathway. Its partners include Almirall, Array BioPharma, and CSL Limited. The company was founded in 2010 and is headquartered in Singapore.Gain TherapeuticsNASDAQ:GANXGain Therapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery and development of allosteric therapies. Its lead drug candidate, GT-02287 for the treatment of GBA1 Parkinson's disease is being evaluated in a Phase 1 clinical trial. Its drug discovery platform Magellan identifies novel allosteric binding sites on disease-implicated proteins and exploits untapped opportunities, by pinpointing pockets that cannot be found or drugged with current technologies. The company's platform is enhanced with new AI and machine-learning tools and virtual screening capabilities to access the emerging on-demand compound libraries covering chemical spaces of approximately 50 billion compounds. It deploys its platform by accelerating drug discovery and unlocking novel disease-modifying treatments for untreatable or difficult-to-treat disorders, including neurodegenerative diseases, rare genetic disorders, and oncology. Gain Therapeutics, Inc. was founded in 2017 and is headquartered in Bethesda, Maryland.Jaguar HealthNASDAQ:JAGXJaguar Health, Inc., a commercial stage pharmaceuticals company, focuses on developing prescription medicines for people and animals with gastrointestinal distress, specifically chronic and debilitating diarrhea. The company operates through two segments, Human Health and Animal Health. It markets Mytesi for the symptomatic relief of noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy. The company also develops Crofelemer, which is in Phase 3 clinical trial for or prophylaxis of diarrhea in adult cancer patients, and to address rare/orphan disease indications, including Short bowel syndrome with intestinal failure and/or congenital diarrheal disorders; supportive care for diarrhea relief in inflammatory bowel diseases; diarrhea-predominant irritable bowel syndrome; and for idiopathic/functional diarrhea. In addition, it develops NP-300, a second-generation proprietary anti-secretory antidiarrheal drug for symptomatic relief and treatment of moderate-to-severe diarrhea; and Canalevia, an oral plant-based drug candidate to treat chemotherapy-induced diarrhea in dogs and exercise-induced diarrhea in dogs. The company was founded in 2013 and is headquartered in San Francisco, California.Landos BiopharmaNASDAQ:LABPLandos Biopharma, Inc., a clinical-stage biopharmaceutical company, discovers and develops oral therapeutics for patients with autoimmune diseases. Its lead product candidate is NX-13, an oral gut-selective Nucleotide Oligomerization Domain (NLRX1), a mitochondria-associated receptor associated with the modulation of inflammatory cytokines that completed Phase Ib clinical trial to treat ulcerative colitis (UC), as well as induce anti-inflammatory effects in CD4+ T cells and other cells in the gastrointestinal tract. The company's preclinical candidates in development include LABP-73, an oral and small molecule NLRX1 pathway agonist in development for the treatment of asthma and chronic obstructive pulmonary disease; LABP-66 is an oral and small molecule NLRX1 pathway agonist for the treatment of multiple sclerosis and Alzheimer's disease; and LABP-69, an oral PLXDC2 agonist for the treatment of diabetic nephropathy and RA. The company has a strategic research collaboration with KU Leuven and University Hospitals Leuven to investigate the effects of NX-13 on epithelial cells with the inflammatory bowel disease. The company was incorporated in 2017 and is headquartered in Blacksburg, Virginia.NeuBase TherapeuticsNASDAQ:NBSENeuBase Therapeutics, Inc., a preclinical-stage biopharmaceutical company, focuses on the development of therapies to treat rare genetic diseases and cancers caused by mutant genes. The company's proprietary modular peptide-nucleic acid antisense oligo (PATrOL) platform focuses on addressing Huntington's disease (HD) and myotonic dystrophy, as well as other genetic disorders, and cancer and oncology applications. Its pipeline includes NT0100 for Huntington's disease; NT0200 for myotonic dystrophy type 1; and NT0300 treatment targets the mutated KRAS gene. NeuBase Therapeutics, Inc. is headquartered in Pittsburgh, Pennsylvania. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.